ArticleCancers2021
Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Synovial Sarcoma: Molecular Biology, Pathology, and Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Relative Dose Intensity of Trabectedin and Outcome of Advanced L-Sarcomas.Cancer medicine · 2025Article
- Systemic inflammation index is a predictive and prognostic factor in patients with liposarcoma or leiomyosarcoma treated with trabectedin.Scientific reports · 2025Article
- Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study.Current oncology (Toronto, Ont.) · 2024Article
- Radiological evaluation of response in patients with locally advanced/metastatic soft tissue sarcoma treated with trabectedin.Frontiers in pharmacology · 2024Article
- Biology and Management of High-Grade Myxofibrosarcoma: State of the Art and Future Perspectives.Diagnostics (Basel, Switzerland) · 2023Review
- Article
- Relapsed Synovial Sarcoma: Treatment Options.Current treatment options in oncology · 2023Review
- Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial.Cancers · 2022Article
- Article
- Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from aFrontiers in oncology · 2022Article
- Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy.European journal of immunology · 2021Article
- Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms.Marine drugs · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 20 institutions in 1 country.
Funding
Abstract
The Italian Sarcoma Group performed this retrospective analysis of patients with advanced soft tissue sarcoma, pretreated with ≥1 anthracycline-based treatment, and treated with trabectedin every three weeks. Primary endpoint was to describe real-life use of trabectedin across Italy. Secondary endpoints included objective response rate (ORR) and safety. Overall, 512 patients from 20 Italian centers were evaluated. Leiomyosarcoma (37.7%)/liposarcoma (30.3%) were the most prevalent histological types (abbreviated as L-sarcoma). Patients received a median of four trabectedin cycles (range: 1-40), mostly as a second-line treatment (~60% of patients). The ORR was 13.7% superior (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.